Diffusion Pharmaceuticals (NASDAQ:DFFN) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFNGet Rating) in a note issued to investors on Friday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright upgraded Diffusion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $9.50 price objective for the company in a report on Tuesday, August 16th.

Diffusion Pharmaceuticals Stock Performance

Shares of DFFN opened at $6.09 on Friday. Diffusion Pharmaceuticals has a 52-week low of $4.64 and a 52-week high of $24.50. The business’s 50 day moving average price is $5.44 and its two-hundred day moving average price is $6.63. The firm has a market cap of $12.42 million, a PE ratio of -0.80 and a beta of 1.47.

Diffusion Pharmaceuticals (NASDAQ:DFFNGet Rating) last issued its quarterly earnings results on Monday, November 14th. The company reported ($1.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.69. Research analysts predict that Diffusion Pharmaceuticals will post -8.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Diffusion Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new stake in shares of Diffusion Pharmaceuticals during the first quarter valued at approximately $106,000. Trexquant Investment LP bought a new stake in Diffusion Pharmaceuticals during the second quarter worth $71,000. Finally, Renaissance Technologies LLC grew its holdings in Diffusion Pharmaceuticals by 8.3% during the first quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company’s stock worth $331,000 after buying an additional 101,100 shares in the last quarter. Institutional investors own 10.25% of the company’s stock.

About Diffusion Pharmaceuticals

(Get Rating)

Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.

Featured Stories

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.